Complete Response to Temozolomide in Metastatic Melanoma After Failure of 5 Lines of Treatment

被引：4
|
作者：
Magge, Tara [1 ]
Shaikh, Hira [2 ]
Chaudhary, Rekha [2 ]
机构：
[1] Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45221 USA
[2] Univ Cincinnati, Dept Hematol & Oncol, Cincinnati, OH USA
来源：
AMERICAN JOURNAL OF THERAPEUTICS | 2022年 / 29卷 / 06期
关键词：
PHASE-III; CHEMOTHERAPY; SURVIVAL; INHIBITORS; NIVOLUMAB; RATES;
D O I：
10.1097/MJT.0000000000001186
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：E767 / E769
页数：3
相关论文
共 50 条
  • [31] Analysis of the microbiome of metastatic melanoma patients with complete response to immunotherapy
    Golcic, M.
    Simetic, L.
    Herceg, D.
    Blazicevic, K.
    Kendel-Jovanovic, G.
    Drazic, I.
    Belancic, A.
    Skocibusic, N.
    Palcevski, D.
    Rubinic, I.
    Vlahovic-Palcevski, V.
    Majnaric, T.
    Dobrila-Dintinjana, R.
    Plestina, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S696 - S696
  • [32] Temozolomide for the treatment of brain metastases associated with metastatic melanoma: A phase II study
    Agarwala, SS
    Kirkwood, JM
    Gore, M
    Dreno, B
    Thatcher, N
    Czarnetski, B
    Atkins, M
    Buzaid, A
    Skarlos, D
    Rankin, EM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2101 - 2107
  • [33] Temozolomide and cisplatin in the treatment of leptomeningeal metastatic involvement from melanoma: a case report
    Salmaggi, A
    Silvani, A
    Eoli, M
    Lamperti, E
    Boiardi, A
    NEUROLOGICAL SCIENCES, 2002, 23 (05) : 257 - 258
  • [34] Complete remission of metastatic melanoma upon BRAF inhibitor treatment - what happens after discontinuation?
    Tolk, Henrike
    Satzger, Imke
    Mohr, Peter
    Zimmer, Lisa
    Weide, Benjamin
    Schaed, Susanne
    Gutzmer, Ralf
    MELANOMA RESEARCH, 2015, 25 (04) : 362 - 366
  • [35] Sustained complete remission after chemobiohormonal therapy for metastatic melanoma
    Stein, ME
    Bernstein, Z
    Drumea, K
    Zalik, M
    Shklar, Z
    Steiner, M
    Haim, N
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (01): : 62 - 64
  • [36] Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma
    Alnabulsi, Reem
    Hussain, Ahsen
    DeAngelis, Dan
    ORBIT-THE INTERNATIONAL JOURNAL ON ORBITAL DISORDERS-OCULOPLASTIC AND LACRIMAL SURGERY, 2018, 37 (05): : 381 - 384
  • [37] Durable complete response in a patient with leptomeningeal melanoma after treatment with dabrafenib, trametinib, and nivolumab
    Lochrin, Sarah E.
    Buonocore, Darren J.
    Young, Robert J.
    Kaley, Thomas J.
    Postow, Michael A.
    Wolchok, Jedd D.
    Shoushtari, Alexander N.
    Momtaz, Parisa
    Warner, Allison S. Betof
    Callahan, Margaret K.
    PIGMENT CELL & MELANOMA RESEARCH, 2024, 37 (06)
  • [38] Durability of response in metastatic melanoma patients after combined treatment with radiation therapy and ipilimumab
    Sodji, Quaovi H.
    Gutkin, Paulina M.
    Swetter, Susan M.
    Reddy, Sunil A.
    Hiniker, Susan M.
    Knox, Susan J.
    MELANOMA MANAGEMENT, 2020, 7 (01) : 7 - 16
  • [39] Final report: Combination of MPC-6827 with temozolomide for the treatment of patients with metastatic melanoma
    Hwu, W.
    Akerley, W. L.
    Stephenson, J.
    Yu, M. K.
    Evans, B. A.
    Mather, G.
    Swabb, E. A.
    Hamid, O.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [40] Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma
    Hillner, BE
    Agarwala, S
    Middleton, MR
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) : 1474 - 1480
12345